GlassScriptPhysician profile
Rachel E Tobler
NPI 1184065583
$6,981.34
in general payments reported to CMS, 2019-2025
16 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $673 · 2023: $1,509 · 2024: $2,193 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234 · Education: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.67 |
| Education | $688.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,583.49 | 2021-2025 | |
| Janssen Biotech, INC. | $1,227.56 | 2022-2025 | Tremfya, Stelara, Remicade |
| Incyte Corporation | $792.19 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $602.74 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $594.83 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $542.76 | 2021-2025 | Dupixent |
| Genzyme Corporation | $405.90 | 2021-2025 | |
| Leo Pharma INC. | $394.44 | 2023-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $272.52 | 2023-2025 | |
| Galderma Laboratories, L.P. | $218.19 | 2024-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.25 | 2023-2025 | Siliq, Jublia |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Sun Pharmaceutical Industries INC. | $64.56 | 2021-2024 | |
| Dermavant Sciences, INC. | $18.34 | 2024 | Vtama |
| Botanix Sb INC | $15.25 | 2025 | Sofdra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $13.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Tobler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.